他莫西芬联合胰激肽原酶治疗少、弱精子症的疗效观察

Curative effect of tamoxifen combined with pancreatic kallikrein on patients of oligoasthenospermia

目的:观察他莫西芬联合胰激肽原酶治疗少、弱精子症患者的疗效。方法:采用随机对照的临床研究,将确诊的130例患者随机分为对照组(60例)和治疗组(70例)。对照组服用Vit E,100mg/次,2次/d;治疗组服用他莫西芬治疗,每次10mg,2次/d,同时联合胰激肽原酶口服,每次120U,3次/d。两组治疗3个月后,分别检测精液质量(精液量、精子浓度、前向运动精子、精浆MDA和SOD)及妊娠率。结果:治疗组在精液量、精子浓度、前向运动精子、精浆MDA和SOD方面较用药前均有显著改善(P<0.05),并在改善精子浓度、前向运动精子、精浆MDA和SOD方面,疗效优于对照组(P<0.05)。结论:他莫西芬联合胰激肽原酶可通过改善氧化应激损伤,进而提高少、弱精子症患者的精子数量和质量,可以作为临床治疗男性不育症的方案。

Objectives： To observe the efficacy of Tamoxifen combined with pancreatic kallikrein in the treatment of patients with oligoasthenospermia. Methods： In the randomized controlled study, 130 diagnosed infer- tile male with oligoasthenospermia were divided into two groups, the control group （60 eases） and the treatment group （70 eases）. The control group received VitE, 100mg once, bid. The treatment group was given Tamoxifen, lOmg, bid, with pancreatic kallikrein, 120 units, tid. After the treatment of 3 months, the semen volume, sperma- tozoa density, prorsad spermatozoa rate, seminal plasma MDA and SOD and pregnancy rate of the two groups were detected. Results： In the treatment group, the index of semen volume, spermatozoa density, prorsad spermatozoa rate, seminal plasma MDA and SOD, were obviously improved compared to pre - treatment （ P 〈 0.05 ）. Besides,it was obviously ameliorated of spermatozoa density, prorsad spermatozoa rate, seminal plasma MDA and SOD com- pared to the control group （P 〈 0. 05 ）. Conclusion： Tamoxifen combined with pancreatic kallikrein can evidently improve the seminal quantity and quality of oligoasthenospermia patients by improving oxidative stress injury, which can serve as an effective clinical treatment in male infertility program.